Soluble amyloid β oligomers may contribute to apoptosis of retinal ganglion cells in glaucoma

Medical Hypotheses

Volumn 71, Issue 1, 2008, Pages 77-80

  Yin, Hongbo ^a   Chen, Lei ^a   Chen, Xiaoming ^a   Liu, Xuyang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; OLIGOMER;

ALZHEIMER DISEASE; APOPTOSIS; ARTICLE; CORRELATION ANALYSIS; DISEASE COURSE; GLAUCOMA; NEUROPROTECTION; NONHUMAN; OLIGOMERIZATION; PATHOGENESIS; PRIORITY JOURNAL; RETINA GANGLION CELL; RISK FACTOR;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; APOPTOSIS; GLAUCOMA; HUMANS; MODELS, BIOLOGICAL; PROTEIN STRUCTURE, QUATERNARY; RETINAL GANGLION CELLS; SOLUBILITY;

EID: 43949126487     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2008.01.030     Document Type: Article

References (24)

1. Quigley H.A., and Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 90 3 (2006) 262-267
2. Gupta N., and Weinreb R.N. New definitions of glaucoma. Curr Opin Ophthalmol 8 (1997) 38-41
3. Weinreb R.N. Glaucoma neuroprotection: what is it? Why is it needed?. Can J Ophthalmol 42 3 (2007) 396-398
4. Guo L., Salt T.E., Luong V., et al. Targeting amyloid-β in glaucoma treatment. PNAS 104 (2007) 13444-13449
5. McKinnon S.J., Lehman D.M., Kerrigan-Baumrind L.A., et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Visual Sci 43 (2002) 1077-1087
6. Yoneda S., Hara H., Hirata A., et al. Vitreous fluid levels of beta-amyloid((1-42)) and tau in patients with retinal diseases. Jpn J Ophthalmol 49 (2005) 106-108
7. Morin P.J., Abraham C.R., Amaratunga A., et al. Amyloid precursor protein is synthesized by retinal ganglion cells, rapidly transported to the optic nerve plasma membrane and nerve terminals, and metabolized. J Neurochem 61 2 (1993) 464-473
8. Golde T.E. Alzheimer disease therapy: can the amyloid cascade be halted?. J Clin Invest 111 (2003) 11-18
9. Walsh D.T., Bresciani L., Saunders D., et al. Amyloid beta peptide causes chronic glial cell activation and neuro-degeneration after intravitreal injection. Neuropathol Appl Neurobiol 31 5 (2005) 491
10. Tamura H., Kawakami H., Kanamoto T., et al. High frequency of open-angle glaucoma in Japanese patients with Alzheimer's disease. J Neurol Sci 246 1-2 (2006) 79-83
11. Bayer A.U., Keller O.N., Ferrari F., et al. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol 133 1 (2002) 135-137
12. Bayer A.U., Ferrari F., and Erb C. High occurrence rate of glaucoma among patients with Alzheimer's disease. Eur Neurol 47 3 (2002) 165-168
13. McKinnon S.J. Glaucoma: ocular Alzheimer's disease?. Front Biosci 8 (2003) s1140-s1156
14. Grace E.A., Rabiner C.A., and Busciglio J. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. Neuroscience 114 (2002) 265-273
15. Gandy S. The role of cerebral amyloid β accumulation in common forms of Alzheimer disease. J Clin Invest 115 5 (2005) 1121-1129
16. Dickson D.W., Crystal H.A., Bevona C., et al. Correlations of synaptic and pathological markers with cognition of the elderly. Neurobiol Aging 16 (1995) 285-298
17. Lue L.F., Kuo Y.M., Roher A.E., et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am J Pathol 155 (1999) 853-862
18. Lacor P.N., Buniel M.C., Furlow P.W., et al. Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J Neurosci 27 4 (2007) 796-807
19. Lambert M.P., Viola K.L., Chromy B.A., et al. Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies. J Neurochem 79 (2001) 595-605
20. Dodart J.C., Bales K.R., Gannon K.S., et al. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci 5 (2002) 452-457
21. Walsh D.M., Klyubin I., Fadeeva J.V., et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416 (2002) 535-539
22. Chromy B.A., Nowak R.J., Lambert M.P., et al. Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42 (2003) 12749-12760
23. Chang L., Bakhos L., Wang Z., et al. Femtomole immunodetection of synthetic and endogenous amyloid-beta oligomers and its application to Alzheimer's disease drug candidate screening. J Mol Neurosci 20 (2003) 305-314
24. Weih L.M., Nanjan M., McCarty C.A., et al. Prevalence and predictors of open-angle glaucoma: results from the visual impairment project. Ophthalmology 108 11 (2001) 1966-1972